Search results for "Type I"

showing 10 items of 966 documents

Branching enzyme deficiency/glycogenosis storage disease type IV presenting as a severe congenital hypotonia: muscle biopsy and autopsy findings, bio…

2010

The fatal infantile neuromuscular presentation of branching enzyme deficiency (glycogen storage disease type IV) due to mutations in the gene encoding the glycogen branching enzyme, is a rare but probably underdiagnosed cause of congenital hypotonia. We report an infant girl with severe generalized hypotonia, born at 33 weeks gestation who required ventilatory assistance since birth. She had bilateral ptosis, mild knee and foot contractures and echocardiographic evidence of cardiomyopathy. A muscle biopsy at 1 month of age showed typical polyglucosan storage. The autopsy at 3.5 months of age showed frontal cortex polymicrogyria and polyglucosan bodies in neurons of basal ganglia, thalamus, …

Pathologymedicine.medical_specialtyMuscle HypotoniaCardiomyopathyAutopsyGlycogen Storage Disease Type IVFatal Outcome14-alpha-Glucan Branching EnzymemedicineGlycogen branching enzymePolymicrogyriaHumansGlycogen storage disease type IVMuscle SkeletalGenetics (clinical)Muscle biopsymedicine.diagnostic_testbiologyInfant NewbornBrainInfantmedicine.diseaseNeurologyPediatrics Perinatology and Child Healthbiology.proteinMuscle HypotoniaFemaleNeurology (clinical)Differential diagnosisInfant PrematureNeuromuscular disorders : NMD
researchProduct

Genetic disorders of connective tissues

1991

Due to the growing knowledge of structure and function of extracellular matrix proteins, congenital abnormalities of connective tissues are identified or suspected in an increasing number of clinical disorders. In osteogenesis imperfecta and two subtypes of Ehlers-Danlos syndrome, the affected matrix proteins were identified and mutations in the corresponding genes (procollagen type I and type III, respectively) could be demonstrated. Some forms of chondrodysplasia were shown to be associated with mutations in the gene encoding for the cartilage-specific collagen (type II). In part, the clinical phenotype is determined by the tissue-specific distribution of these collagens. However, the cor…

Pathologymedicine.medical_specialtyMutationbusiness.industryOsteoarthritisOsteogenesis ImperfectaMatrix (biology)medicine.disease_causemedicine.diseaseProcollagen Type IPhenotypeExtracellular matrixPhenotypeRheumatologyOsteogenesis imperfectaMutationmedicineHumansCollagenConnective Tissue DiseasesbusinessGeneCurrent Opinion in Rheumatology
researchProduct

Remodeling of peritoneal-like structures by mesothelial cells: its role in peritoneal healing.

1999

Abstract Background. Intraabdominal adhesions are a common complication following laparotomy. Since the exact mechanisms involved in this processes are unknown we have analyzed in vitro the role of mesothelial cells in peritoneal healing. Material and methods. Human mesothelial cells from omental tissue were cultivated for 2 weeks in a three-dimensional culture either on or in a collagen type I matrix. The effects of blood and collagen matrix were analyzed by exposing mesothelial cells to an overlying blood clot, simulating intraperitoneal bleeding, or a second collagen layer. The production of collagen types III and IV, fibronectin, and laminin was analyzed with immunohistochemical methods…

Pathologymedicine.medical_specialtyTissue AdhesionsMatrix (biology)BiologyPeritoneal DiseasesCollagen Type IIIPeritoneumLamininmedicineHumansCells CulturedWound HealingEpithelial CellsImmunohistochemistryExtracellular MatrixFibronectinsMesotheliumFibronectinmedicine.anatomical_structureCell culturebiology.proteinSurgeryCollagenPeritoneumMesothelial CellThe Journal of surgical research
researchProduct

Spatial and temporal heterogeneity of ventilator-associated lung injury after surfactant depletion.

2008

Volutrauma and atelectrauma have been proposed as mechanisms of ventilator-associated lung injury, but few studies have compared their relative importance in mediating lung injury. The objective of our study was to compare the injury produced by stretch (volutrauma) vs. cyclical recruitment (atelectrauma) after surfactant depletion. In saline-lavaged rabbits, we used high tidal volume, low respiratory rate, and low positive end-expiratory pressure to produce stretch injury in nondependent lung regions and cyclical recruitment in dependent lung regions. Tidal changes in shunt fraction were assessed by measuring arterial Po2 oscillations. After ventilating for times ranging from 0 to 6 h, lu…

Pathologymedicine.medical_specialtyVentilator-associated lung injuryPhysiologyNitric Oxide Synthase Type IIInflammationEnzyme-Linked Immunosorbent AssayPulmonary EdemaRespiratory physiologyLung injuryPhysiology (medical)medicineAnimalsInterleukin 8LungChemokine CCL2PeroxidaseLungVentilators Mechanicalbusiness.industryRespiratory diseaseInterleukin-8Pulmonary SurfactantsLung Injuryrespiratory systemmedicine.diseasePulmonary edemarespiratory tract diseasesOxygenmedicine.anatomical_structureNeutrophil InfiltrationCalibrationRespiratory MechanicsCytokinesFluid TherapyFemaleRabbitsmedicine.symptomBlood Gas AnalysisChemokinesbusinessJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

DNA strand breaks induced by nuclear hijacking of neuronal NOS as an anti-cancer effect of 2-methoxyestradiol

2015

2-Methoxyestradiol (2-ME) is a physiological metabolite of 17β-estradiol. At pharmacological concentrations, 2-ME inhibits colon, breast and lung cancer in tumor models. Here we investigated the effect of physiologically relevant concentrations of 2-ME in osteosarcoma cell model. We demonstrated that 2-ME increased nuclear localization of neuronal nitric oxide synthase, resulting in nitro-oxidative DNA damage. This in turn caused cell cycle arrest and apoptosis in osteosarcoma cells. We suggest that 2-ME is a naturally occurring hormone with potential anti-cancer properties.

Pathologymedicine.medical_specialtyneuronal nitric oxide synthaseCell cycle checkpoint2-methoxyestradiolDNA damageAntineoplastic AgentsApoptosisBone NeoplasmsNitric Oxide Synthase Type Imedicine.disease_causeNitric OxideNitric oxidechemistry.chemical_compoundReactive nitrogen specieCell Line TumormedicineHumans2-MethoxyestradiolReactive nitrogen speciesCytokinesisOsteosarcomaEstradiolbusiness.industryDNA BreaksIntracellular Signaling Peptides and ProteinsCancermedicine.diseaseReactive Nitrogen SpeciesG2 Phase Cell Cycle CheckpointsOxidative StressOncologychemistryApoptosis2-methoxyestradiol; Neuronal nitric oxide synthase; Nitric oxide; Osteosarcoma; Reactive nitrogen species; OncologyCancer researchM Phase Cell Cycle CheckpointsbusinessTumor Suppressor p53-Binding Protein 1Oxidative stressmedicine.drugResearch Paper
researchProduct

Methods for a prompt and reliable laboratory diagnosis of Pompe disease : report from an international consensus meeting

2008

Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data gener…

Pediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDiseaseBiochemistryEarly initiationchemistry.chemical_compoundEndocrinologyInternal medicineGlycogen storage disease type IIGeneticsmedicineHumansMolecular BiologyAcarboseMuscle biopsyGlycogenmedicine.diagnostic_testClinical Laboratory TechniquesGlycogen Storage Disease Type IIbusiness.industryInfantEnzyme replacement therapymedicine.diseasePompe disease; laboratory diagnosisEndocrinologychemistryAcid alpha-glucosidaseGlucan 14-alpha-Glucosidasebusinessmedicine.drug
researchProduct

Clinical and Genetic Aspects of Juvenile Onset Pompe Disease

2021

AbstractLittle is known about clinical symptomatology and genetics of juvenile onset Pompe disease (JOPD). The aims of this study were to analyze how these children are diagnosed, what clinical problems they have, and how phenotype is related to genotype. To accomplish this, we analyzed retrospectively data of 34 patients diagnosed after their first and before completion of their 18th birthday. Median age at diagnosis was 3.9 (range 1.1–17) years. Eight patients (23.5%) developed initial symptoms in the first year, 12 (35%) between 1 and 7 years, and 6 (18%) thereafter. Eight (23.5%) had no clinical symptoms at the time of diagnosis. Indications for diagnostics were a positive family histor…

Pediatricsmedicine.medical_specialtyGeneralized muscle weaknessDisease03 medical and health sciences0302 clinical medicineGenotypeHumansMedicineFamily historyRetrospective Studies030304 developmental biology0303 health sciencesGlycogen Storage Disease Type IIbusiness.industryHypertrophic cardiomyopathyMuscle weaknessalpha-GlucosidasesGeneral Medicinemedicine.disease3. Good healthPhenotypeJuvenile onsetMutationPediatrics Perinatology and Child HealthFailure to thriveNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryNeuropediatrics
researchProduct

Immunobiology of normal and diabetic pregnancy

1990

The International Congress of Immunobiology of Normal and Diabetic Pregnancy brought together a heterogeneous group of workers to consider one of the most fascinating areas of immunology. The meeting, which proved to be a thinkshop as much as a workshop, developed along two major lines: (1) an examination of new data in normal pregnancy immunology, from both the research and clinical points of view and (2) analysis of the suspected problems of diabetic pregnancy. 'Suspected' because pregnancy-related problems in diabetic women are not due solely to metabolic disturbances, but also involve immunological aspects of diabetes, particularly where type I diabetes is concerned.

Pediatricsmedicine.medical_specialtyHeterogeneous groupbusiness.industryInternational congressDiabetes mellitusImmunologyMedicineType i diabetesNormal pregnancybusinessmedicine.diseaseDiabetic pregnancyImmunology Today
researchProduct

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

2019

Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centers and countries participated in the project. Subsequently, individ…

Pediatricsmedicine.medical_specialtyInternational CooperationFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyTreatment resultsAntibodies Monoclonal HumanizedFHHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineTotal cholesterolmedicineHumansMass ScreeningEffective treatment030212 general & internal medicineScreenPro FHLDL-CAlirocumabInternational networkEvidence-Based Medicine Clinical Trials and Their Interpretations (L. Roever Section Editor)business.industryAnticholesteremic AgentsIncidencePCSK9 InhibitorsScreen and treatmedicine.diseaseEvolocumab3. Good healthEuropeEvolocumabProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessDelivery of Health CareAlirocumabCurrent Atherosclerosis Reports
researchProduct

Diagnostik und Therapie des Morbus Pompe im Kindesalter

2020

Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced enzyme activity results in abnormal intra- and extralysosomal glycogen deposition as well as impaired cellular function and autophagy. Age at manifestation and severity of disease depend on residual enzyme activity. Enzyme replacement therapy (ERT) is available since 2006. In infantile onset Pompe disease, the most severe form, markedly prolonged survival has resulted in a new phenotype with symptoms and problems not encountered previously. In addition, it became apparent that antibody formation against the recombinant human enzyme may adversely affect the response to ERT. This review summari…

Pediatricsmedicine.medical_specialtybiologybusiness.industryAutophagy030232 urology & nephrologyMedizinGlycogen deposition610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.diseaseEnzyme assay03 medical and health sciences0302 clinical medicine10036 Medical Clinic030225 pediatricsPediatrics Perinatology and Child HealthGlycogen storage disease type IImedicinebiology.proteinbusinessAntibody formation
researchProduct